15 February 2020 by Raymond Benza

Case Study of Long-Term Safety, Tolerability, And Hemodynamic Response of Pb1046, A Sustained-Release Analogue for Vasoactive Intestinal Peptide (VIP), in an Adult Subject With Pulmonary Arterial Hypertension (PAH)


PB1046 is an investigational neuropeptide, VIP, genetically fused to an elastin-like biopolymer, for treatment of PAH, with biologic effects mediated by two receptors, VPAC1 and VPAC2, belonging to the family B of G protein-coupled receptors. VPAC receptors are in the pulmonary and systemic circulation. The safety and accuracy of the CardioMEMS™ HF System, which monitors pulmonary artery (PA) pressure from a sensor implanted into the PA, have been previously documented, along with correlations with Swan-Ganz measurements and echocardiography.


The multi-dose safety, PK, and VIP-based pharmacodynamic effects of PB1046 were evaluated in an open-label, multi-dose Phase 1 pilot study in PAH patients who have a permanently implanted CardioMEMS™. PB1046 was administered weekly subcutaneously x 8 weeks (extended due to subjective improvements) at dose levels previously tested and shown to be safe.


Three patients completed study with no related serious adverse events/symptomatic hypotension/syncope. PB1046 appears to be well tolerated with only mild injection site erythema. The available PK profile data confirmed the dose-related but less than dose proportional increase in study drug exposure profile observed in previous studies. CardioMEMS™ hemodynamic monitoring demonstrated reductions in mean PA pressure and total pulmonary resistance and increases in stroke volume and cardiac output without an increase in heart rate with PB1046. Long-term PB1046 therapy (over 18 months) in one subject demonstrated clinically meaningful improvements in all the hemodynamic parameters assessed, which were sustained for three months afterwards, suggesting a possible disease modifying effect of PB1046 (Figure 1) and will be presented.


The preliminary data for PB1046 support continued evaluation as a potential novel therapy for PAH patients that is safe and well tolerated. Improvements in hemodynamic parameters associated with PB1046 support the ongoing randomized, double-blind, parallel group Phase II PAH study assessing 16 weeks of PB1046 treatment for NYHA/WHO functional class II and III PAH patients.

Key Contributors

Raymond L. Benza, Sumita Paul, Murali Chakinala, Priscilla Correa, John Lee, and James White

Comments (0)

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI